News and Announcements
Actinogen Medical’s Progress with Alzheimer’s Trial
- Published September 08, 2016 11:12AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st September 2016, Actinogen
It’s been some months since our last update on Actinogen Medical and the development program for Xanamem™. Over this time we’ve made significant progress in harmonisation of the Phase II XanADu protocol and we have every expectation that all approvals for the study will be in place with the first patients recruited by the end of the year. It’s clear that through the recent interaction with the US Food & Drug Administration (FDA) we have a better, more comprehensive protocol that will provide a stronger data-set for Xanamem™ in the treatment of mild Alzheimer’s disease.
To view the full article, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
